Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000905148-25-002815
Filing Date
2025-08-11
Accepted
2025-08-11 16:55:43
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8974
2 jfa.htm EX-1 6084
  Complete submission text file 0000905148-25-002815.txt   16868
Mailing Address 260 ARSENAL PLACE, SUITE 1 WATERTOWN MA 02472
Business Address 260 ARSENAL PLACE, SUITE 1 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Subject) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94162 | Film No.: 251202746
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 855 BOYLSTON STREET 10TH FLOOR BOSTON MA 02116
Business Address 855 BOYLSTON STREET 10TH FLOOR BOSTON MA 02116 857-201-5983
K2 HealthVentures Equity Trust LLC (Filed by) CIK: 0001948604 (see all company filings)

EIN.: 842128131 | State of Incorp.: MA | Fiscal Year End: 1231
Type: SCHEDULE 13G